Your browser doesn't support javascript.
loading
Consideration for Coronavirus Disease 2019 Drug Treatment in Patients with Epilepsy on Antiepileptic Drugs
Article de Ko | WPRIM | ID: wpr-926308
Bibliothèque responsable: WPRO
ABSTRACT
Several medications are approved to treat coronavirus disease 2019 (COVID-19) in Korea including nirmatrelvir/ritonavir, remdesivir, and regdanvimab. There is potential drug-drug interaction between antiepileptic drugs (AEDs) and the medications used to treat COVID-19. Several AEDs such as phenytoin, carbamazepine, phenobarbital, and primidone are strong cytochrome P450 inducers and can inhibit the drugs used for COVID-19. Particularly, these drugs are contraindicated with nirmatrelvir/ritonavir (Paxlovid®). There is a weaker drug-drug interaction between the AEDs and remdesivir. No significant interaction has been reported between the AEDs and molnupiravir. Pharmacokinetic interactions of the AEDs are important in effective management of COVID-19 in patients with epilepsy.
Texte intégral: 1 Indice: WPRIM langue: Ko Texte intégral: Journal of the Korean Neurological Association Année: 2022 Type: Article
Texte intégral: 1 Indice: WPRIM langue: Ko Texte intégral: Journal of the Korean Neurological Association Année: 2022 Type: Article